JVMSX
Price
$27.43
Change
-$0.32 (-1.15%)
Updated
Jun 13 closing price
Net Assets
21.46B
SMVZX
Price
$11.93
Change
-$0.17 (-1.40%)
Updated
Jun 13 closing price
Net Assets
1.51B
Interact to see
Advertisement

JVMSX vs SMVZX

Header iconJVMSX vs SMVZX Comparison
Open Charts JVMSX vs SMVZXBanner chart's image
JHancock Disciplined Value Mid Cap R2
Price$27.43
Change-$0.32 (-1.15%)
VolumeN/A
Net Assets21.46B
Virtus Ceredex Mid-Cap Value Equity R6
Price$11.93
Change-$0.17 (-1.40%)
VolumeN/A
Net Assets1.51B
JVMSX vs SMVZX Comparison Chart
Loading...
View a ticker or compare two or three
VS
JVMSX vs. SMVZX commentary
Jun 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JVMSX is a StrongBuy and SMVZX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
JVMSX has more cash in the bank: 21.5B vs. SMVZX (1.51B). SMVZX pays higher dividends than JVMSX: SMVZX (1.27) vs JVMSX (0.43). JVMSX was incepted earlier than SMVZX: JVMSX (13 years) vs SMVZX (11 years). JVMSX (1.26) is less costly to investors than SMVZX (0.88). SMVZX is a more actively managed with annual turnover of: 141.00 vs. JVMSX (47.00). JVMSX has a lower initial minimum investment than SMVZX: JVMSX (0) vs SMVZX (2500000). JVMSX annual gain was more profitable for investors over the last year : -3.29 vs. SMVZX (-4.38). JVMSX return over 5 years is better than : 50.13 vs. SMVZX (23.76).
JVMSXSMVZXJVMSX / SMVZX
Total Expense Ratio1.250.79158%
Annual Report Gross Expense Ratio1.260.88143%
Fund Existence13 years11 years-
Gain YTD2.313-1.160-199%
Front LoadN/AN/A-
Min. Initial Investment02500000-
Min. Initial Investment IRAN/AN/A-
Net Assets21.5B1.51B1,424%
Annual Yield % from dividends0.431.2734%
Returns for 1 year-3.29-4.3875%
Returns for 3 years15.8015.29103%
Returns for 5 years50.1323.76211%
Returns for 10 years33.43-4.56-733%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ELEV0.38N/A
+0.39%
Elevation Oncology
ICLR145.66-1.43
-0.97%
ICON plc
AKBA3.56-0.09
-2.47%
Akebia Therapeutics
AEIS122.80-3.88
-3.06%
Advanced Energy Industries
SLN5.33-0.26
-4.57%
Silence Therapeutics Plc